1266100-22-4

Basic information

• Product Name: C₄₄H₅₇N₅O₁₁
• Synonyms: C₄₄H₅₇N₅O₁₁
• CAS NO: 1266100-22-4
• Molecular Weight: 831.963
• Mol File: 1266100-22-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₄₄H₅₇N₅O₁₁(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₄H₅₇N₅O₁₁(1266100-22-4)
• EPA Substance Registry System: C₄₄H₅₇N₅O₁₁(1266100-22-4)

Safety Data

• Hazardous Substances Data: 1266100-22-4(Hazardous Substances Data)

Upstream product

• 1264241-01-1 allyl N-2-[(2S,4R)-4-[(tert-butoxycarbonyl)-amino]-2-(hydroxymethyl)tetrahydro-1H-pyrrol-1-yl]-2-oxoethyl-N-methylcarbamate 
• 1266099-95-9 5-allyl 1-benzyl (2S)-2-[[(5-hydroxy-1,2-dimethyl-1H-indol-3-yl)carbonyl](methyl)amino]pentanedioate 
• 1264239-47-5 C₂₁H₂₂N₂O₈S 
• 1264243-44-8 tert-butyl (3R,5S)-5-(hydroxymethyl)pyrrolidin-3-ylcarbamate hydrochloride 
• 132245-80-8 C₂₀H₂₇NO₆ 
• 1264239-56-6 (S)-5-allyl 1-benzyl 2-(methylamino)pentanedioate hydrochloride 
• 1264239-51-1 C₂₂H₂₄N₂O₈S 
• 1264239-42-0 C₁₅H₁₉NO₄*ClH 
• 132286-79-4 N-α-(t-butoxycarbonyl)-L-glutamic γ-allyl ester 
• 100-39-0 benzyl bromide 

Relevant articles and documents

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y1, as modulators of the serotonin receptor of subtype 5-HT2B, as blockers of the voltage-gated potassium channel Kv1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.